Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of CAM2029 versus octreotide LAR or lanreotide ATG in advanced GEP-NET
MOH_2022-05-22_010757Phase 3Not yet recruiting
- Sponsor
- Camurus
- Start
- May 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of octreotide hydrochloride in Gastroenteropancreatic Carcinoid Tumor (2 arms), sponsored by Camurus. Planned start May 2022; status: not yet recruiting.
02
Drugs
octreotide hydrochloride
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on MOH_2022-05-22_010757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-22_010757.